Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERRFI1
REST API REST API
Homo sapiens
ERRFI1 is differentially expressed in 164 experiments: 62 organism parts: liver, spleen, ... (60 more);, 83 disease states: normal, adrenocortical carcinoma, ... (81 more);, 47 cell types 310 cell lines 24 compound treatments and 42 other conditions.
Synonyms GENE-33, MIG-6, RALT
Orthologs ERRFI1 (2 of 2) (Danio rerio)   Errfi1 (Mus musculus)   ERRFI1 (Gallus gallus)   A0JN98_BOVIN (Bos taurus)   ERRFI1 (1 of 2) (Danio rerio)   Errfi1 (Rattus norvegicus)   errfi1 (Xenopus laevis)   ERRFI1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, negative regulation of epidermal growth factor receptor signaling pathway, protein binding, cytoplasm, negative regulation of peptidyl-tyrosine phosphorylation, kinase binding, response to stress, protein kinase binding, nucleus, Rho GTPase activator activity, lung vasculature development, regulation of keratinocyte differentiation, lung alveolus development, extrinsic to internal side of plasma membrane, skin morphogenesis, lung epithelium development, negative regulation of protein autophosphorylation, positive regulation of Rho GTPase activity, negative regulation of epidermal growth factor-activated receptor activity
InterPro Term GTPase_binding, Inhibitor_Mig-6
UniProt Accession Q9UJM3
Search EB-eye ENSG00000116285
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-8167, E-MTAB-37, E-GEOD-803, E-TABM-34, E-GEOD-6573, ... (12 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-4219, E-GEOD-3202, E-GEOD-19466, ... (25 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
RKOE6
1
E-MTAB-37
U251
1
E-GEOD-20089
RPMI 8226
1
E-MEXP-921
304 more value(s).


Cell type

studied in E-GEOD-15893, E-GEOD-18811, E-GEOD-20193, E-GEOD-20033, E-TABM-130, ... (21 experiments)

Factor Value U/D Experiments
stromal cell
2
E-MEXP-2034, E-GEOD-1460
T cell
1
E-GEOD-13987
adult choroid from 76 y.o. donor
1
E-GEOD-18811
chondrocyte
1
E-TABM-130
astrocyte
1
E-GEOD-4483
CD34 positive
1
E-GEOD-12662
41 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-16363, E-MTAB-680, E-GEOD-13987, ... (25 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
normal
3
4
E-GEOD-3307, E-TABM-702, E-GEOD-13987, E-GEOD-23878, E-GEOD-10927, ... (7 experiments)
Partially decidualised
1
E-MTAB-680
extranodal NK/T-cell lymphoma
1
E-TABM-702
colorectal cancer
1
E-GEOD-15960
Fetal Adenoma
1
E-MEXP-2442
77 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-MEXP-1958, E-MEXP-2590, E-GEOD-2706, ... (13 experiments)

Factor Value U/D Experiments
AMP
1
E-MEXP-2285
Cxcl12
1
E-GEOD-7307
unknown
1
E-GEOD-7307
bacterial endotoxin
1
E-GEOD-3284
baseline sevoflurane
1
E-GEOD-4386
LDL
1
E-GEOD-5741
18 more value(s).


Biosource provider

studied in E-MTAB-37

Factor Value U/D Experiments
DSMZ
1
E-MTAB-37


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-19246, E-GEOD-21589, E-GEOD-16363

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-MEXP-2283

dfs time (months)
studied in E-GEOD-21653

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-TABM-868, E-MEXP-1648, E-TABM-601, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

Growth condition
studied in E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-20540, E-GEOD-9764, ... (9 experiments)

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-MEXP-2069, E-TABM-666, ... (17 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Karyotype
studied in E-GEOD-7214

Lymph node status
studied in E-GEOD-6532

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Phenotype
studied in E-GEOD-26495, E-GEOD-1460, E-GEOD-17636

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1857, E-MEXP-1315, E-MEXP-2759

sample status
studied in E-GEOD-30573

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Processing time: 0.346 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM